Business
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO's DNA immunotherapy candidate, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and c
About this update from Akeso, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Novel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute ","length":225,"tagName":"p"}]},{"val":[{"type":"text","content":"Study builds on the previously reported positive Phase II results involving INO-5401 in GBM, adding a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding.","length":246,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":690,"olType":false},{"type":"text","content":"HONG KONG and PLYMOUTH MEETING, Pa., March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO's DNA immunotherapy candidate, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care, Inc., which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026.","length":826,"tagName":"p"},{"type":"text","content":"Cadonilimab has received marketing approval in China for several indications, including first-line gastric cancer, first-line cervical cancer, and second/third-line cervical cancer, demonstrating effectiveness irrespective of PD-L1 expression status. As the world's first approved bispecific antibody for cancer immunotherapy, cadonilimab has established its clinical value through real-world application and validation across multiple Phase III trials. The drug is currently involved in over 11 Phase...